Pub 100-03 Medicare National Coverage Determinations: Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration
Guidance announcing that effective for claims with dates of service on and after April 3, 2013, CMS will expand coverage of OPT with verteporfin for “wet” AMD. CMS is revising the requirements for testing to permit either optical coherence tomography (OCT) or FA to assess treatment response. This revision is a national coverage determination (NCD), and thus has broad applicability.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: June 14, 2013
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.